Yanxia Liu1, Xiaoxiang Tian1, Shan Liu1, Dan Liu1, Yang Li1, Meili Liu1, Xiaolin Zhang1, Chenghui Yan2, Yaling Han3. 1. Department of Cardiology and Cardiovascular Research Institute, General Hospital of Northern Theater Command, Shenyang, China. 2. Department of Cardiology and Cardiovascular Research Institute, General Hospital of Northern Theater Command, Shenyang, China. Electronic address: yanch1029@163.com. 3. Department of Cardiology and Cardiovascular Research Institute, General Hospital of Northern Theater Command, Shenyang, China. Electronic address: hanyaling@263.net.
Abstract
OBJECTIVE: Cellular repressor of E1A-stimulated genes (CREG), a vasculoprotective molecule, is significantly downregulated in atherosclerotic vessels through unclear mechanisms. While epigenetic regulation is involved in atherosclerosis development, it is not known if the CREG gene is epigenetically regulated. The aim of this study was to assess the potential role of CREG methylation in contributing to atherosclerosis. APPROACH AND RESULTS: Overexpression of DNA methyltransferase (DNMT)3B significantly inhibited CREG expression in human umbilical vein endothelial cells (HUVECs) and human coronary aortic endothelial cells (HCAECs).Conversely, inhibition of DNA methylation with 5-aza-2'-deoxycytidine (5-aza-dC) dose-dependently increased CREG expression. A CREG promoter analysis identified +168 to +255 bp as a key regulatory region and the CG site at +201/+202 bp as a key methylation site. The transcription factor GR-α could bind to the +201/+202 bp CG site promoting CREG transcription, a process significantly inhibited by DNMT3B overexpression. Treatment of cells with oxidized low-density lipoprotein (ox-LDL), a critical atherosclerogenic factor, significantly increased DNMT3B expression, increasing CREG promotor methylation, blocking GR-α binding, and inhibiting CREG expression. Consistently, CG sites in the CREG promoter fragment were hyper-methylated in human atherosclerotic arteries, and CREG expression was significantly reduced. A negative correlation between DNMT3B and CREG expression levels was observed in human atherosclerotic arteries. Finally, Ox-LDL-induced endothelium dysfunction was significantly attenuated by both 5-aza-dC and an anti-oxidative molecular N-acetylcysteine (NAC) administration through rescue the expression of CREG and activation of the p-eNOS/NO pathway. CONCLUSIONS: Our study provides the first direct evidence that DNMT3B-mediated CREG gene hypermethylation is a novel mechanism that contributes to endothelial dysfunction and atherosclerosis development. Blocking CREG methylation may represent a novel therapeutic approach to treat ox-LDL-induced atherosclerosis.
OBJECTIVE: Cellular repressor of E1A-stimulated genes (CREG), a vasculoprotective molecule, is significantly downregulated in atherosclerotic vessels through unclear mechanisms. While epigenetic regulation is involved in atherosclerosis development, it is not known if the CREG gene is epigenetically regulated. The aim of this study was to assess the potential role of CREG methylation in contributing to atherosclerosis. APPROACH AND RESULTS: Overexpression of DNA methyltransferase (DNMT)3B significantly inhibited CREG expression in human umbilical vein endothelial cells (HUVECs) and human coronary aortic endothelial cells (HCAECs).Conversely, inhibition of DNA methylation with 5-aza-2'-deoxycytidine (5-aza-dC) dose-dependently increased CREG expression. A CREG promoter analysis identified +168 to +255 bp as a key regulatory region and the CG site at +201/+202 bp as a key methylation site. The transcription factor GR-α could bind to the +201/+202 bp CG site promoting CREG transcription, a process significantly inhibited by DNMT3B overexpression. Treatment of cells with oxidized low-density lipoprotein (ox-LDL), a critical atherosclerogenic factor, significantly increased DNMT3B expression, increasing CREG promotor methylation, blocking GR-α binding, and inhibiting CREG expression. Consistently, CG sites in the CREG promoter fragment were hyper-methylated in human atherosclerotic arteries, and CREG expression was significantly reduced. A negative correlation between DNMT3B and CREG expression levels was observed in human atherosclerotic arteries. Finally, Ox-LDL-induced endothelium dysfunction was significantly attenuated by both 5-aza-dC and an anti-oxidative molecular N-acetylcysteine (NAC) administration through rescue the expression of CREG and activation of the p-eNOS/NO pathway. CONCLUSIONS: Our study provides the first direct evidence that DNMT3B-mediated CREG gene hypermethylation is a novel mechanism that contributes to endothelial dysfunction and atherosclerosis development. Blocking CREG methylation may represent a novel therapeutic approach to treat ox-LDL-induced atherosclerosis.
Authors: Julie E Goodwin; Xinbo Zhang; Noemi Rotllan; Yan Feng; Han Zhou; Carlos Fernández-Hernando; Jun Yu; William C Sessa Journal: Arterioscler Thromb Vasc Biol Date: 2015-02-19 Impact factor: 8.311
Authors: S Ehara; M Ueda; T Naruko; K Haze; A Itoh; M Otsuka; R Komatsu; T Matsuo; H Itabe; T Takano; Y Tsukamoto; M Yoshiyama; K Takeuchi; J Yoshikawa; A E Becker Journal: Circulation Date: 2001-04-17 Impact factor: 29.690
Authors: W S Post; P J Goldschmidt-Clermont; C C Wilhide; A W Heldman; M S Sussman; P Ouyang; E E Milliken; J P Issa Journal: Cardiovasc Res Date: 1999-09 Impact factor: 10.787
Authors: Alexander Akhmedov; Izabela Rozenberg; Francesco Paneni; Giovanni G Camici; Yi Shi; Carola Doerries; Anna Sledzinska; Pavani Mocharla; Alexander Breitenstein; Christine Lohmann; Sokrates Stein; Tobias von Lukowicz; Michael O Kurrer; Jan Borén; Burkhard Becher; Felix C Tanner; Ulf Landmesser; Christian M Matter; Thomas F Lüscher Journal: Eur Heart J Date: 2014-01-12 Impact factor: 29.983
Authors: Kalima B Timizheva; Abdulbary A M Ahmed; Amira Ait Aissa; Anna V Aghajanyan; Leyla V Tskhovrebova; Madina M Azova Journal: Life (Basel) Date: 2022-02-07